

# CURRICULUM VITAE

**LANIE E. EAGLETON, M.D.**

## **CURRENT WORK INFORMATION**

Work Address	Postal address	Southern Illinois University School of Medicine P.O. Box 19636 Springfield, IL 62794-9636
	Physical Address	701 North First Street, Room D434 Springfield, Illinois 62702
	Clinic Address	Southern Illinois University School of Medicine Pulmonary Medicine Clinic 751 North Rutledge Street Springfield, IL 62794-9652

## **EDUCATION**

06/01/59		East Richland High School Olney, Illinois
06/09/63	B.A.	Hamilton College Clinton, N.Y.
06/15/67	M.D.	Harvard University School of Medicine Boston, Mass.

## **POST GRADUATE TRAINING**

1967-68	Intern in Medicine University of Virginia Hospitals Charlottesville, VA
1968-70	Assistant Resident in Medicine University of Virginia Hospitals Charlottesville, VA
1972-74	Resident Chest Service Bellevue Hospital, NY

## **PROFESSIONAL BACKGROUND**

Medical Licensure	Illinois #036-052906-1 DEA #AE7624946
Certification	National Board of Medical Examiners Diplomate (#95189) 07-01-68 American Board of Internal Medicine (#34660) 1) Qualifying Exam Cert 10-10-70 2) Diplomate in Internal Medicine 10-15-74 3) Diplomate in Subspecialty of Pulmonary Disease 10-15-74 4) Diplomate in Subspecialty of Critical Care 1987

Military Status

Surgeon Reserve Corps Public  
Health Service,  
U.S. Department of Health,  
Education and Welfare  
Appointed Asst. Surgeon 11-13-67  
Active Duty Surgeon 06-30-70  
Honorable Inactivation 06-30-72  
Serial #30011

Societies & Associations

National Honor Society 05-20-58  
Phi Beta Kappa 01-01-63  
Nassau County Medical Soc  
09-24-74  
American Medical Assn 09-24-74  
American College of Physicians  
American College of Chest Physicians  
American Thoracic Society  
American Sleep Disorders Assn  
Member Executive Board and Asst  
Treasurer 1978-1995  
ALA of Illinois  
Illinois Lung Assn Delegate at Large,  
Lincoln Land Lung Assn 1977  
to present  
Chairman of Nomination Committee  
of ATS 1984  
President, ALA of Illinois  
1989-1991

Academic Appointments

Teaching Assistant  
University of Virginia  
Charlottesville, VA 1968-70  
  
Teaching Assistant  
New York University School of  
Medicine  
New York, NY 1972-74  
  
Instructor in Medicine  
New York University School of  
Medicine  
New York, NY 1974-76  
  
Assistant Professor and Chief  
Division of Pulmonary Medicine  
Department of Medicine  
SIU School of Medicine  
Springfield, IL 1976-80  
  
Associate Professor and Chief  
1980-98  
  
Professor and Chief  
1998  
  
Professor  
1999

Clinical Appointments	Clinical Professor	1999-present
	Bellevue Hospital, New York, NY Clinical Assistant Attending Physician	1974
	Manhattan VA Hospital New York, NY Attending Physician	1974
	New York Infirmary, New York, NY Assistant Attending Physician Chief, Pulmonary Disease & Respiratory Therapy	1975
	Memorial Medical Center Chief of Pulmonary Division & Medical Director of Respiratory Therapy	1976-present
	St. John's Hospital Associate Staff	1976-present
	Cystic Fibrosis Care Center Affiliate Program Director	1981-present

## **RESEARCH PROJECTS AND FUNDING**

Co-Investigator: "Manifestations of Sleep Apnea in Diabetics". Principal Investigator: Joseph Q. Henkle, M.D. Funding: American Lung Association of DuPage and McHenry Counties; 1988; \$7,000.

Co-Investigator: "Comparison of Oral Cefpodoxime Proxetil and in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease (COPD) in Adult Patients". Principal Investigator: Joseph Q. Henkle, M.D.; Funding: Upjohn; 1990; \$45,112.

Co-Investigator: "A Multicenter, Double-Blind, Placebo-Controlled Phase II Study of the Effects of rhIGF-I in Malnourished Ventilator-Dependent Patients". Principal Investigator: Joseph Q. Henkle, M.D. Funding: Genentech, Inc.; 1991; \$110,000.

Principal Investigator: "Azithromycin Respiratory Infection Study (ARIS)". Funding: Medical and Technical Research Associates (MRTA); 1991; \$6,200.

Co-Investigator: "Molecular Genetics of Aspergillus Pathogenicity". Principal Investigator: Peter T. Borgia, Ph.D.; Funding: American Lung Association of Illinois; 1992-1994; \$24,000.

Principal Investigator: "Support of Pulmonary Fellowship Research". Funding: Memorial Medical Center Foundation; 1994-1997; \$32,602.

Co-Investigator: "The Relationship between Changes in FEV1.0 and Peak Flow Rate and Changes in Airway Obstruction in Patients with Asthma." Principal Investigator: Carl Lawyer, MD.; Funding: Forest Labs; 1995; equipment.

Co-Investigator: "Treatment of Active Histoplasmosis with GM-CSF Combined with Itraconazole vs Placebo with Itraconazole." Principal Investigator: Carl Lawyer, MD.; Funding: Immunex; \$2,500 per patient.

Principal Investigator: Epidemiologic Study of Cystic Fibrosis: A Multicenter, Longitudinal Follow-Up Study of Patients with Cystic Fibrosis for Monitoring Pulmonary Function, Pulmonary Exacerbations, and Safety of Long-Term Treatment with Pulmozyme® (dornase alfa)". Funding: Genentech, Inc.: 1994 -1997; \$175 per patient per year; 1997-2002; \$100 per patient per year.

Co-Investigator: "The Relationship of Respiratory Autonomic Dysfunction to HLA-DR3/4 Phenotype in Type I Diabetics." Principal Investigator: Patricia Hopkins-Price, PhD.; Funding: Southern Illinois University School of Medicine Central Research Committee; 1995; \$2,500.

Principal Investigator: "A Prospective, Randomized, Comparative Study of Ciprofloxacin and Clarithromycin for the Treatment of Acute Exacerbations of Chronic Bronchitis." Funding: Bayer, Corporation; 1997; \$300 per patient.

Principal Investigator: "The Role of Education and Intervention Strategies in Cost Containment in Patients with Chronic Obstructive Pulmonary Disease". Project within "Patient Outcomes in Primary Care Settings and Their Relationship with Educational Interventions." Principal Investigators: David E. Steward, M.D. and Beth Dawson, Ph.D.; Funding: SIU – Excellence in Academic Medicine, 1997 – 1998; \$14,000 of \$40,150.

Principal Investigator: "Multicenter, Open-Label, Study of Clarithromycin for the Treatment of Mild to Moderate Acute Exacerbation on Chronic Bronchitis (Phase IV)." Funding: Abbott; 1998; \$100 per patient.

Principal Investigator: "A Prospective, Randomized, Controlled, Multi-Center Clinical Trial of Ciprofloxacin 500mg BID for 10 days versus Cefuroxime Axetil 250mg BID for 10 Days for the Treatment of Patients with Acute Sinusitis." Funding: Bayer Corporation, 12/15/97 – 12/15/98. \$300 per patient.

Co-Investigator: "A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of 12 Weeks of 2 Oral Doses (200mg and 400mg Once Daily) of PROVIGIL® (Modafinil) as Treatment for Adults with Excessive Daytime Sleepiness Associated with Obstructive Sleep Apnea/Hypopnea Syndrome Followed by a 12-Month Open-Label Extension; Study No. C1538a/303/US-UK". Principal Investigator: Joseph Q. Henkle, M.D. Funding: Cephalon Corporation, 03/10/00 - ongoing. \$12,312.50 per patient.

Co-Investigator: "A Randomized, Double-Blind, Placebo-Controlled, Parallel Study of the Efficacy and Safety of (S) - Zopiclone in the Treatment of Adult Subjects with Primary Insomnia Followed by Optional Open-Label Chronic Dosing for up to One Year, Version 3.0, dated 28 February 2001; Study No. 190-046". Principal Investigator: Joseph Q. Henkle, M.D. Funding: Sepracor, Incorporated, 04/20/01-12/14/01. \$12,355 per patient.

Co-Investigator: "A Prospective, Multicenter Study of the Anemia of Critical Illness and Transfusion in the Critically Ill Patient (Protocol PR00-15-010)". Principal Investigator: Elamin M. Elamin, MD. Funding: Ortho Biotech, Inc.; 2000; \$4,000.

Co-Investigator: "A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of 12 Weeks of 2 Oral Doses (200 mg and 400 mg Once Daily) of PROVIGIL® (Modafinil) as Treatment for Adults with Excessive Daytime Sleepiness Associated with Obstructive Sleep Apnea/Hypopnea Syndrome Followed by a 12-Month Open-Label Extension; Study No. C1538a/303/US-UK"; Principal Investigator: Joseph Q. Henkle, M.D.; Funding: Cephalon Corporation; 2000; \$12,312.50 per patient.

Co-Investigator: "A Randomized, Double-Blind, Placebo-Controlled, Parallel Study of the Efficacy and Safety of (S)-Zopiclone in the Treatment of Adult Subjects with Primary Insomnia Followed by Optional Open-Label Chronic Dosing for up to One Year, Version 3.0, dated 28 February 2001; Study No. 190-046"; Principal Investigator: Joseph Q. Henkle, M.D.; Funding: Sepracor, Incorporated; 2001; \$12,355 per patient.

Co-Investigator: "Actimmune Safe and Appropriate Use Program (ASAP®) Registry". Principal Investigator: M. Haitham Bakir, M.D. Funding: InterMune, Inc.; 2002; \$3,200.

Co-Investigator: "A Double Blind, Placebo Controlled, Parallel Multi-Center Study On Extended VTE Prophylaxis In Acutely Ill Medical Patients With Prolonged Immobilization Protocol XRP4563C/3501 ("EXCLAIM")"; Principal Investigator: Elamin M. Elamin, MD; Funding: Aventis; 2002; \$42,880.

Principal Investigator: "Epidemiologic Study of Cystic Fibrosis: A Multicenter, Longitudinal Follow-Up Study of Patients with Cystic Fibrosis for Monitoring Pulmonary Function, Pulmonary Exacerbations, and Safety of Long-Term Treatment with Pulmozyme® (dornase alfa)"; Funding: Genentech, Inc.; 2003; \$100 per patient.

Co-Investigator: "A comparison of ipratropium bromide/salbutamol delivered by the Respimat® inhaler to ipratropium bromide Respimat®, COMBIVENT® Inhalation Aerosol and Placebo of each formulation in a 12-week, double-blind, safety and efficacy study in adults with chronic obstructive pulmonary disease." (Protocol No. 1012.46); Principal Investigator: Joseph Q. Henkle, M.D.; Funding: Boehringer Ingelheim Pharmaceuticals, Inc.: 2003; \$10,000 per patient.

Co-Investigator: "An Epidemiologic Study of Xolair® (Omalizumab): Evaluating Clinical Effectiveness And Long-Term Safety In Patients With Moderate to Severe Asthma" (EXCELS) (Protocol Q2948g); Principal Investigator: Joseph Q. Henkle, MD; Funding: Genentech, Inc.

Co-Investigator: "Evaluation of the Long-Term Efficacy and Safety of Zolpidem-MR 12.5-mg Compared to Placebo, when Both Are Administered over a Long-Term Period "as Needed", in Patients with Chronic Primary Insomnia. (A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicentre, Phase IIIb Clinical Study). (LTE5407: "ZOLONG") Principal Investigator: Joseph Q. Henkle, M.D.; Funding: Sanofi-Aventis, Inc., 2004

Co-Investigator: "A Randomized, Double-Blind, Parallel-Group, 52-week Study to Compare the Effect of the Fluticasone Propionate/Salmeterol DISKUS Combination Product 250/50mcg BID with Salmeterol DISKUS 50mcg BID on the Annual Rate of Moderate/Severe Exacerbations in Subjects with Chronic Obstructive Pulmonary Disease (COPD)". (Protocol SCO100250) Principal Investigator: Joseph Q. Henkle, M.D.; Funding: GlaxoSmithKline, 2005

Co- Investigator: "A prospective observational study for the psychometric validation of a patient-reported questionnaire in acute exacerbation of chronic obstructive pulmonary disease (AECOPD) (Protocol #:OPL 104226)" SCRIHS # 05-151; Principal Investigator: Joseph Q. Henkle, MD; Funding: GlaxoSmithKline, 2006

Co- Investigator: "Psychometric Validation of a Subject-Administered Questionnaire to Assess Cough and Sputum in Patients with COPD Associated with Chronic Bronchitis and Chronic Bronchitis (Not Obstructed)." (Cough and Sputum Validation Study PROTOCOL NO.:1219.2) SCRIHS # 06-017; Principal Investigator: Joseph Q. Henkle, MD; Funding: Boehringer Ingelheim, 2006

## **PUBLICATION & RESEARCH**

Carmichael, S.M., **Eagleton ,L.**, Ayers, C.R., et al. 1970. Orthostatic hypotension during vincristine therapy. *Archives of Int Med*, 126(2): 290-293.

**Eagleton, L.E.**, Rosher, R., Hawe, A., Bilinsky, R. 1979. Radiation therapy and mechanical dilation of endobronchial obstructions secondary to Wegener's granulomatosis. *Chest*, 76 (5) 609-610.

**Eagleton, L.E.** 1979. "Proneness to Asthma," *Clinical Forum on Asthma*, 3:2.

Shrake, K., Hinkle, G., **Eagleton, L.E.** 1979. The use of hypoxic and hypercarbic challenge in the diagnosis of ventilatory receptor dysfunction. *Resp Care*, 24: (5) 426-430.

**Eagleton, L.E.** 1980. "First Asthma Camp in Illinois," *Illinois Med J*, 158:6, 390-391.

Deep, G.S., Eagleton, L.E. 1980. Resolution of influenzal pneumonia managed with PEEP and corticosteroids, *Illinois Med J*, 158:2, 76-78.

Markman, M., **Eagleton, LE.** 1981. Paradoxical clinical improvement and radiographic deterioration in anergic patients treated for far advanced tuberculosis (letter). *New England Journal of Medicine*, 305(3):167.

Barlett, P.C., Von Behren, L.A., Tewari, R.P., Martin, R.J., **Eagleton, L.E.**, Issac, M.J., Kulkarni, P.S. 1982.

Eagleton, LE

Bats in the belfrey: an outbreak of histoplasmosis, *Am J of Public Health*, 72:12, 1369-1372.

Soler, N.G., **Eagleton, L.E.** 1982. Autonomic neuropathy and the ventilatory responses of diabetics to progressive hypoxemia and hypercarbia. *Diabetes*, 31: 609-614.

Stiff, P.J., **Eagleton, L.E.**, Hindman, T., Braud, E., Koester, A.R., Widner, M.K. 1987. Autologous stem cell transplantation using peripheral blood stem cells. *Transplantation*. 44(4); 585-588.

Wortsman, J., **Eagleton, L.E.**, Rosner, W., Dufau, M. 1987. Mechanism for the hypotestosteronemia of the sleep apnea syndrome. *The American Journal of the Medical Sciences*, 293: 221.

Barenfanger, J., Ramirez, F., Tewari, R.P. and **Eagleton, L.** 1989. Pulmonary phaeohyphomycosis with chronic hemoptysis. *Chest*, 95:1158-1160.

Khardori, R., **Eagleton, L.E.**, Soler, N.G., McConnachie, P.R. 1991. Lymphocytic interstitial pneumonitis in autoimmune thyroid disease. *The American Journal of Medicine*, 90, 649-652.

Shrake, K.L., Scaggs, J.E., England, K.R., Henkle, J.Q., and **Eagleton, L.E.** 1994. Benefits associated with a respiratory care assessment-treatment program: Results of a pilot study. *Respiratory Care*, 39:7, 715-724..

Borgia, P.T., Dodge, C.L., **Eagleton, L.E.**, and Adams, T.H. 1994. Bidirectional gene transfer between *Aspergillus fumigatus* and *Aspergillus nidulans*. *FEMS Microbiology Letters*, 122:3, 227-231.

Borgia, P.T., **Eagleton, L.E.**, and Miao, Y. 1994. DNA preparations from *Aspergillus* and other filamentous fungi. *Biotechniques*, 17:3, 430, 432

Lawyer, C., Pai, S., Watabe, M., Bakir, H., **Eagleton, L.**, and Watabe, K. 1996. Effects of synthetic form of tracheal antimicrobial peptide on respiratory pathogens. *Journal of Antimicrobial Chemotherapy*. 37, 599-604.

Lawyer, C; Watabe, M; Pai, S; Bakir, H; **Eagleton, L**; Mashimo, T; and Watabe, K. 1996. A synthetic form of tracheal antimicrobial peptide has both bactericidal and antifungal activities. *Drug Des Discov*, 14(3):171-178

Shrake, K.L., Scaggs, J.E., England, K.R., Henkle, J.Q., **Eagleton, L.E.** 1996. A respiratory care assessment-treatment program: results of a retrospective study. *Respiratory Care*, 41:8, 703-713.

Lawyer, C., Pai, S., Watabe, M., Borgia, P., Mashimo T., **Eagleton, L.**, Watabe, K. 1996. Antimicrobial activity of a 13 amino acid tryptophan-rich peptide derived from a putative porcine precursor protein of a novel family of antibacterial peptides. *FEBS Letters*, 390 (1):95-98.

Sood, A, Dawson, B, Eid, W, **Eagleton, L**, Henkle, J, Hopkins-Price, P. (2006) Obesity is associated with bronchial hyper-responsiveness in women but not in men. *Journal of Asthma*, 42 (10):847-852.

Sood A, Dawson B, Layous F, **Eagleton L**, Henkle J, Hopkins-Price P. (2006) Effect of choice of reference standard on classification of severity of spirometric abnormality submitted to *Journal of Chronic Obstructive Pulmonary Disease*

Suhail F, Heikal M, Hughes L, Hopkins-Price P, Henkle J, Eagleton L. (2008) Pulmonary Function in Patients with Aspirin Induced Asthma (AIA). Manuscript in preparation

## **ABSTRACTS**

**Eagleton, L.E.**, Soler, N.G. 1981. Hypoventilation in response to hypoxemia in diabetics. *Chest*, 80:3.

**Eagleton, L.E.**, Soler, N.G. 1981. Beta adrenergic receptor binding on lymphocyte and polymorphonuclear membranes of asthmatics with cough. *Chest*, 80:3.

**Eagleton, L.E.**, VonBehren, L.A., Haas, J.A., Henkle, J.Q. 1990. Bronchoconstriction by pentamidine and methacholine in patients with HIV infection. *American Review of Respiratory Disease*, 141:4 (part 2), A151. March 7, 2008

**Eagleton, L.E.**, Scaggs, J., Henkle, J.Q. 1990. Pulmonary aspergillosis in patients with cystic fibrosis. *American Review of Respiratory Disease*, 141:4 (part 2), A815.

Bakir, H., **Eagleton, L.E.**, Hopkins-Price, P., Colle, J., and Henkle, J.Q. 1993. Histoplasmosis in cystic fibrosis patients. *American Journal of Respiratory & Critical Care Medicine*, 149:4 (part 2), A666.

Despot, JE and **Eagleton, LE.** 1994. Defects in immunoglobulin G (IgG), IgG subclasses, and antibody production in non-HIV patients with pulmonary disease due to mycobacterium avium-intracellulare (MAI). *Journal of Allergy and Clinical Immunology*, 93:1 (part 2), A170

Bakir, M.H., Lawyer, C.H., Hopkins-Price, P.L, **Eagleton, L.**, and Dawson, B. 1995 . Discordant responses to beta agonist post methacholine. *American Journal of Respiratory & Critical Care Medicine*, 151:4 (part 2), A273.

Hopkins-Price, P.L., Lawyer, C.H., **Eagleton, L.E.**, Henkle, J.Q., Burch, S.G., and Despot, J.E. Methacholine reactive patients have a lower resting MVV: Retrospective study of 1000 patients. *American Journal of Respiratory & Critical Care Medicine*, 151:4 (part 2), A119.

Despot, JE., **Eagleton, LE.** 1995. IgG & IgG1 increase with treatment of mycobacterium avium-intracellulare (MAI) lung disease in non-HIV patients. *J Allergy Clin Immunol*, 95 (1 part 2); A244.

Lawyer, C., Pai, S., Watabe, M., Bakir, H., **Eagleton, L.**, Watabe, K. 1996. Effects of synthetic tracheal antimicrobial peptide on pseudomonas aeruginosa. *American Journal of Respiratory & Critical Care Medicine*, 153:4 (part 2), A706.

Despot, J.E., Henkle, J.Q., Lawyer, C.H., **Eagleton, L.E.** 1996. The incidence of a cystic fibrosis (CF mutation) in non-HIV patients with other chronic pulmonary processes, especially mycobacterium avium complex (MAC). *American Journal of Respiratory & Critical Care Medicine*, 153:4 (part 2), A704.

Hopkins-Price, P., Lawyer, C., Bakir, H., Chorjel, A., **Eagleton, L.**, Despot, J. 1996. Can resting pulmonary function tests predict maximal oxygen uptake in patients with dyspnea? *American Journal of Respiratory & Critical Care Medicine*, 153:4 (part 2), A655.

Hopkins-Price, P., Scott, J., Lawyer, C., Aboukoura, F., **Eagleton, L.**, Griffin, J. 1996. Can peak flow rate predict forced expiratory volume in asthmatics? *American Journal of Respiratory & Critical Care Medicine*, 153:4 (part 2), A519.

Henkle, J.Q., Vijil Jr, J., Hopkins-Price, P., Griffin, M., Lawyer, C.H., **Eagleton, L.E.** 1996. Prevalence of diabetes in sleep apnea patients. *American Journal of Respiratory & Critical Care Medicine*, 153:4 (part 2), A355.

Aboukoura, F., Jamal, M., **Eagleton, L.E.**, Hopkins-Price, P., Dawson, B., Griffin, M. 1997. Impact of smoking on patients with cystic fibrosis. *American Journal of Respiratory & Critical Care Medicine*, 155 (4 part 2), A639.

**Eagleton, L.E.**, Leonard, R., Dawson, B. 2000. The rate of change in DLCO in patients with hyperresponsive airway. *American Journal of Respiratory & Critical Care Medicine*. Accepted

**Eagleton, L.E.**, Leonard, R., Dawson, B., Henkle, J.Q., and Hopkins-Price, T. May, 2000. Prevalence of airway hyper-responsiveness among patients with severe emphysema who are or are not smokers. *American Gerontology*. Abstract

Eid, W., Dawson, B., Hopkins-Price, P., Vijil, Jr., J., **Eagleton, L.**, Henkle, J., Sood, A. 2002. Association between bronchial hyperreactivity and body mass index in adults. *Respiratory and Critical Care Medicine*. 165(8), A435

Layous, F., Dawson, B., Hopkins-Price, P., **Eagleton, L.**, Vigil Jr, J., Henkle, J., Sood, A. 2002. Association between bronchial hyperreactivity and body mass index in children in central Illinois. *Chest*. 122 (4), 55S (Abstract). (Selected as one of 20 winning abstracts of the 2002 CHEST Foundation Young Investigators Awards).

Layous F, Dawson B, Hopkins-Price P, **Eagleton L**, Vigil Jr J, Henkle J, Sood A. 2003. The effect of choice of reference equation on analysis of pulmonary function tests. *Am J Resp Crit Care Med*, 167 (7), A421 (Abstract)

Sood, A, Verhulst, S, **Eagleton, L**, Henkle, J, Hopkins-Price, P. 2005. Is Obese Asthmatic Airway More Reactive Than Non-Obese Asthmatic Airway? *Am J Resp Crit Care Med*, Proceedings of the American Thoracic Society, 2 (Abstracts Issue), A849.

Sood, A, Verhulst, S, Varma, A, **Eagleton, L**, Henkle, J, Hopkins-Price, P. 2006. Association of Excess Weight and Degree of Airway Responsiveness in Asthmatics and Non-Asthmatics. *Journal of Asthma*, Vol 43 (6), 447-452. (Abstract)

Heikal, M, Hopkins-Price, P, Sunbuli, M, Henkle, J, **Eagleton, L**. 2007. Epidemiology and Pulmonary Functions in Patients with Aspirin Induced Asthma. *Am J Resp Crit Care Med*, 175 (Abstracts Issue), A909.

Revised March 2008